Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (DE:0K4)
BERLIN:0K4
Akero Therapeutics (0K4) Stock Price & Analysis
2 Followers
0K4 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€10.80 - €55.00
Previous Close€18.29
Volume0.00
Average Volume (3M)146.00
Market Cap
€1.26B
Enterprise Value€772.86M
Total Cash (Recent Filing)$550.01M
Total Debt (Recent Filing)$25.78M
Price to Earnings (P/E)N/A
Beta-0.71
Next Earnings
May 14, 2024EPS Estimate
-€0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding56,297,528
10 Day Avg. Volume0
30 Day Avg. Volume146
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.07
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.91
Forecast
1Y Price Target
€45.23Price Target Upside147.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Akero Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyAkero's efruxifermin (EFX) demonstrates potential to significantly improve liver fibrosis, with unprecedented results showing 75% of patients achieving at least a one-stage fibrosis improvement.
Financial StabilityAkero's strong financial position, with substantial cash reserves, positions the company to advance its lead drug candidate efruxifermin without the immediate need for additional financing.
Regulatory MilestoneA successful End-of-Phase 2 meeting with the FDA for Akero's efruxifermin may accelerate the drug’s approval process, enhancing the company's growth prospects.
Bears Say
Clinical Trials DelayThe next significant clinical update for efruxifermin is not expected until a future date, potentially limiting short-term stock upside.
Drug Safety ConcernsSafety and tolerability concerns, such as gastrointestinal side effects and bone density loss, may limit the drug's use to more advanced cases.
Market CompetitionCompetitive market dynamics, particularly with the presence of GLP-1s, could pose challenges to the drug's commercial success.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.14% Other Institutional Investors
99.86% Public Companies and
Individual Investors
0K4 FAQ
What was Akero Therapeutics Inc’s price range in the past 12 months?
Akero Therapeutics Inc lowest stock price was €10.80 and its highest was €55.00 in the past 12 months.
What is Akero Therapeutics Inc’s market cap?
Currently, no data Available
When is Akero Therapeutics Inc’s upcoming earnings report date?
Akero Therapeutics Inc’s upcoming earnings report date is May 14, 2024 which is in 10 days.
How were Akero Therapeutics Inc’s earnings last quarter?
Akero Therapeutics Inc released its earnings results on Feb 29, 2024. The company reported -€0.924 earnings per share for the quarter, missing the consensus estimate of -€0.773 by -€0.151.
Is Akero Therapeutics Inc overvalued?
According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued.
Does Akero Therapeutics Inc pay dividends?
Akero Therapeutics Inc does not currently pay dividends.
What is Akero Therapeutics Inc’s EPS estimate?
Akero Therapeutics Inc’s EPS estimate is -€0.84.
How many shares outstanding does Akero Therapeutics Inc have?
Currently, no data Available
What happened to Akero Therapeutics Inc’s price movement after its last earnings report?
Akero Therapeutics Inc reported an EPS of -€0.924 in its last earnings report, missing expectations of -€0.773. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Akero Therapeutics Inc?
Among the largest hedge funds holding Akero Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Akero Therapeutics Inc’s shares valued at 55M.
---
Akero Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€45.23 (147.27% Upside)
€45.23 (147.27% Upside)
Blogger Sentiment
Bullish
DE:0K4 Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $115.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.33%
12-Months-Change
Fundamentals
Return on Equity
-35.22%
Trailing 12-Months
Asset Growth
62.74%
Trailing 12-Months
Company Description
Akero Therapeutics Inc
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
---
0K4 Stock 12 Months Forecast
Average Price Target
€45.23
▲(147.27% Upside)
Technical Analysis
Akero Therapeutics
―
Allogene Therapeutics
―
Fate Therapeutics
―
Amarin
―
Avid Bioservices
―
Best Analysts Covering 0K4
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-8.73%
reiterated a buy rating 2 months ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -8.73% per trade.
---